Table 1.

Practice variability among participating collection sites

Survey queries and responses (N = 6)No. of responses (%)
Patient age group  
Adults 1 (16.7%) 
Pediatrics 1 (16.7%) 
Adult and pediatrics 4 (67%) 
Pediatric patient age range  
0-18 y 2 (33.3%) 
0-21 y 1 (16.7%) 
0-35 y 1 (16.7%) 
No response 2 (33.3%) 
Pre-collection RBC transfusion type  
Manual whole blood exchange 1 (16.7%) 
Simple RBC transfusion 4 (66.7%) 
Automated RCE 6 (100%) 
Pre-collection transfusion number of sessions  
Manual whole blood exchange  
2 sessions 1 (16.7%) 
Simple RBC transfusion  
0-1 sessions 1 (16.7%) 
2-3 sessions 1 (16.7%) 
3 sessions 1 (16.7%) 
6 sessions 1 (16.7%) 
Automated RCE  
1 sessions 1 (16.7%) 
2 sessions 1 (16.7%) 
2-3 sessions 1 (16.7%) 
3 sessions 2 (33.3%) 
3-5 sessions 1 (16.7%) 
Precollection RBC transfusion frequency  
3 wk 1 (16.7%) 
4 wk 5 (83%) 
Last precollection RBC transfusion prior to PBSC collection (d)  
2 (33.3%) 
1-3 1 (16.7%) 
1 (16.7%) 
1 (16.7%) 
10 1 (16.7%) 
Posttransfusion HbS percentage  
5-15% 1 (16.7%) 
15% 2 (33.3%) 
22% 1 (16.7%) 
30% 2 (33.3%) 
Apheresis collection instrument  
Spectra Optia 6 (100%) 
Fenwal Amicus 
Spectra Optia protocol  
cMNC 3 (50%) 
MNC 1 (16.7%) 
No answer 2 (33.3%) 
Total blood volumes processed per procedure  
4 total blood volumes 3 (50%) 
No answer 3 (50%) 
Plerixafor administration prior to collection (h)  
2 h 2 (33.3%) 
2-3 h 1 (16.7%) 
4 h 3 (50%) 
Precollection peripheral blood CD34+ cell count on day 1 (CD34+ cells/μL)  
0.2 1 (16.7%) 
25 1 (16.7%) 
30 2 (33.3%) 
35 1 (16.7%) 
41 1 (16.7%) 
Anticoagulant: whole blood ratio  
1:13 1 (16.7%) 
1:12 2 (33.3%) 
1:10 2 (33.3%) 
No answer 1 (16.7%) 
Target color of the collect line  
Second lightest color 1 (16.7%) 
Second darkest color 1 (16.7%) 
Between the 2 darkest colors 3 (50%) 
No response 1 (16.7%) 
Collection efficiency (CE2 formula)  
35 2 (33.3%) 
43 1 (16.7%) 
45 1 (16.7%) 
No answer 2 (33.3%) 
Number of collection cycles  
2 (33.3%) 
3 (50%) 
No answer 1 (16.7%) 
CD34+ cells/kg yield per day  
1 x 106 1 (16.7%) 
3 x 106 2 (33.3%) 
4 x 106 1 (16.7%) 
6.46 x 106 1 (16.7%) 
No answer 1 (16.7%) 
Product TNC count  
3 x 109 1 (16.7%) 
4 x 109 1 (16.7%) 
No answer 4 (66.7%) 
CD34+ cell viability (%)  
97% 1 (16.7%) 
99% 1 (16.7%) 
99-100% 1 (16.7%) 
100% 1 (16.7%) 
No answer 2 (50%) 
Product hematocrit (%)  
2% 1 (16.7%) 
7% 1 (16.7%) 
5-8% 1 (16.7%) 
12% 1 (16.7%) 
No answer 2 (33.3%) 
TBV to process  
Fixed TBV 2 (33.3%) 
Fixed TBV or liters of whole blood 1 (16.7%) 
Fixed time 2 (33.3%) 
Prediction algorithm 1 (16.7%) 
Criteria to proceed with PBSC collection  
No 4 (66.7%) 
Yes  
Minimum peripheral blood CD34+ cell count 1 (16.7%) 
10 1 (16.7%) 
Collection parameter altered  
Collection preference 4 (80%) 
Increasing collection days 1 (16.7%) 
No answer 1 (16.7%) 
Survey queries and responses (N = 6)No. of responses (%)
Patient age group  
Adults 1 (16.7%) 
Pediatrics 1 (16.7%) 
Adult and pediatrics 4 (67%) 
Pediatric patient age range  
0-18 y 2 (33.3%) 
0-21 y 1 (16.7%) 
0-35 y 1 (16.7%) 
No response 2 (33.3%) 
Pre-collection RBC transfusion type  
Manual whole blood exchange 1 (16.7%) 
Simple RBC transfusion 4 (66.7%) 
Automated RCE 6 (100%) 
Pre-collection transfusion number of sessions  
Manual whole blood exchange  
2 sessions 1 (16.7%) 
Simple RBC transfusion  
0-1 sessions 1 (16.7%) 
2-3 sessions 1 (16.7%) 
3 sessions 1 (16.7%) 
6 sessions 1 (16.7%) 
Automated RCE  
1 sessions 1 (16.7%) 
2 sessions 1 (16.7%) 
2-3 sessions 1 (16.7%) 
3 sessions 2 (33.3%) 
3-5 sessions 1 (16.7%) 
Precollection RBC transfusion frequency  
3 wk 1 (16.7%) 
4 wk 5 (83%) 
Last precollection RBC transfusion prior to PBSC collection (d)  
2 (33.3%) 
1-3 1 (16.7%) 
1 (16.7%) 
1 (16.7%) 
10 1 (16.7%) 
Posttransfusion HbS percentage  
5-15% 1 (16.7%) 
15% 2 (33.3%) 
22% 1 (16.7%) 
30% 2 (33.3%) 
Apheresis collection instrument  
Spectra Optia 6 (100%) 
Fenwal Amicus 
Spectra Optia protocol  
cMNC 3 (50%) 
MNC 1 (16.7%) 
No answer 2 (33.3%) 
Total blood volumes processed per procedure  
4 total blood volumes 3 (50%) 
No answer 3 (50%) 
Plerixafor administration prior to collection (h)  
2 h 2 (33.3%) 
2-3 h 1 (16.7%) 
4 h 3 (50%) 
Precollection peripheral blood CD34+ cell count on day 1 (CD34+ cells/μL)  
0.2 1 (16.7%) 
25 1 (16.7%) 
30 2 (33.3%) 
35 1 (16.7%) 
41 1 (16.7%) 
Anticoagulant: whole blood ratio  
1:13 1 (16.7%) 
1:12 2 (33.3%) 
1:10 2 (33.3%) 
No answer 1 (16.7%) 
Target color of the collect line  
Second lightest color 1 (16.7%) 
Second darkest color 1 (16.7%) 
Between the 2 darkest colors 3 (50%) 
No response 1 (16.7%) 
Collection efficiency (CE2 formula)  
35 2 (33.3%) 
43 1 (16.7%) 
45 1 (16.7%) 
No answer 2 (33.3%) 
Number of collection cycles  
2 (33.3%) 
3 (50%) 
No answer 1 (16.7%) 
CD34+ cells/kg yield per day  
1 x 106 1 (16.7%) 
3 x 106 2 (33.3%) 
4 x 106 1 (16.7%) 
6.46 x 106 1 (16.7%) 
No answer 1 (16.7%) 
Product TNC count  
3 x 109 1 (16.7%) 
4 x 109 1 (16.7%) 
No answer 4 (66.7%) 
CD34+ cell viability (%)  
97% 1 (16.7%) 
99% 1 (16.7%) 
99-100% 1 (16.7%) 
100% 1 (16.7%) 
No answer 2 (50%) 
Product hematocrit (%)  
2% 1 (16.7%) 
7% 1 (16.7%) 
5-8% 1 (16.7%) 
12% 1 (16.7%) 
No answer 2 (33.3%) 
TBV to process  
Fixed TBV 2 (33.3%) 
Fixed TBV or liters of whole blood 1 (16.7%) 
Fixed time 2 (33.3%) 
Prediction algorithm 1 (16.7%) 
Criteria to proceed with PBSC collection  
No 4 (66.7%) 
Yes  
Minimum peripheral blood CD34+ cell count 1 (16.7%) 
10 1 (16.7%) 
Collection parameter altered  
Collection preference 4 (80%) 
Increasing collection days 1 (16.7%) 
No answer 1 (16.7%) 

cMNC, continuous mononuclear cell; MNC, mononuclear cell; SD, standard deviation; TBV, total blood volume; TNC, total nucleated cells.

or Create an Account

Close Modal
Close Modal